Scientists are making the case that a vaccine against rhinoviruses, the predominant cause of the common cold, is achievable.
The quest for a vaccine against rhinoviruses may have seemed quixotic, because there are more than 100 varieties circulating around the world. Even so, the immune system can handle the challenge, researchers from Emory University School of Medicine and Children’s Healthcare of Atlanta say.
Vaccines that combine dozens of varieties of rhinovirus at once are effective in stimulating antiviral antibodies in mice and monkeys, the researchers report in Nature Communications. The paper was also posted on Biorxiv before publication.
“We think that creating a vaccine for the common cold can be reduced to technical challenges related to manufacturing,” says Martin Moore, PhD, associate professor of pediatrics at Emory University School of Medicine.
Rhinoviruses are the most common cause of the common cold; other viruses such as respiratory syncytial virus, parainfluenza virus and adenoviruses can cause them too. Rhinoviruses also exacerbate asthma attacks. Although they come in many varieties, rhinoviruses do not drift to the same degree that influenza viruses do, Moore says.
Researchers showed in the 1960s that it was possible to vaccinate people against one variety of rhinovirus and prevent them from getting sick when challenged with samples of the same virus. The trouble was the sheer diversity of rhinoviruses – or that’s how it appeared at the time.
“It’s surprising that nobody tried such a simple solution over the last 50 years. We just took 50 types of rhinovirus and mixed them together into our vaccine, and made sure we had enough of each one,” Moore says. “If we make a vaccine with 50 or 100 variants, it’s the same amount of total protein in a single dose of vaccine. The variants are like a bunch of slightly different Christmas ornaments, not really like 50 totally different vaccines mixed.”
A mixture of 25 types of inactivated rhinovirus can stimulate neutralizing antibodies against all 25 in mice, and a mixture of 50 types can do the same thing in rhesus macaques. In this paper, antibodies generated in response to the vaccine were tested for their ability to prevent the virus from infecting human cells in culture. However, the vaccines were not tested for their ability to stop animals from getting sick.
“There are no good animal models of rhinovirus replication,” Moore says. “The next step would be human challenge models with volunteers, which are feasible because the virus is not very pathogenic.”
Emory has optioned the vaccine technology to a startup company, Meissa Vaccines, Inc., which is pursuing a product development plan with support from the National Institute of Allergy and Infectious Diseases’ vaccine manufacturing services.
Learn more: Vaccine vs many common cold viruses achievable
The Latest on: Vaccine against rhinoviruses
[google_news title=”” keyword=”vaccine against rhinoviruses” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Vaccine against rhinoviruses
- Noticeable increase in vaccination against papillomavirus since the implementation of a college campaign launched in October 2023on April 25, 2024 at 6:31 pm
Since the start of the campaign in middle school, vaccination of adolescents against the papillomavirus has seen a notable increase in France, including in community News ...
- Venezuela broke its HPV vaccine promises, and there's barely any sex ed. Experts say it's a problemon April 25, 2024 at 7:27 am
Venezuela’s government has repeatedly broken its promise to provide vaccines against HPV for free, and many public-school teachers ignore the requirement to teach sex ed. President Nicolás Maduro’s ad ...
- Meningitis survivor advocates against changing vaccine scheduleon April 19, 2024 at 7:50 am
The CDC recommends the meningococcal conjugate (MenACWY) vaccine for all preteens and teens. The current vaccine schedule recommends 11 to 12-year-olds should get a MenACWY vaccine, with a booster ...
- DNA vaccine against Zika performs well in tests on miceon April 18, 2024 at 9:47 am
In Brazil, researchers at the University of São Paulo (USP) and the Pernambuco division of Oswaldo Cruz Foundation (FIOCRUZ) are developing a Zika vaccine. The formulation was tested on mice and found ...
- Hospital admissions spike in an uncommon season as Blank Children's Hospital reaches capacityon April 18, 2024 at 7:26 am
It is an uncommon time of the year to see illnesses spike, but doctors say this could be due to isolation for children born during the COVID-19 pandemic.
- New Vaccine Could Protect Against Any Strain of a Virus With One Shoton April 18, 2024 at 6:43 am
Scientists seem to be close to creating a so-called "universal vaccine" that can protect against any strain of virus and is safe even for the immunocompromised and babies. In a press release from the ...
- A one-shot vaccine for COVID, flu and future viruses? Researchers say it's comingon April 18, 2024 at 2:30 am
But what if it were possible to protect against COVID and the flu, and other unknown viruses that haven't yet emerged, with just one shot? If that became reality, seasonal or annual boosters would be ...
- Ask A Doctor: What Are The Common Types Of Infections That Are More Likely To Occur In Low Temperature Environments?on April 16, 2024 at 2:28 pm
This article examines the risk of infections due to low temperature, with expert opinions from two doctors. The article discusses common infections such as the flu, colds, bronchitis, and pneumonia, ...
- Genetics-based universal vaccine could be effective against any viral strainon April 16, 2024 at 7:32 am
Genetics-based "one-and-done" vaccines for the flu and COVID-19 could prove more effective and easier to craft than current jabs, researchers report.
via Bing News